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Introduction
Metastatic disease is the major cause of breast cancer 
mortality and is typically resistant to conventional and 
experimental therapies. Th   e 5-year survival rate for meta-
static breast cancer remains below 25% [1]. It is impera-
tive to develop breast cancer management strategies that 
are based on detection and treatment before or soon 
after metastatic spread [2] in order to improve this 
situation. Mammographic screening strategies are intended 
to accomplish this by detecting cancers before metastatic 
dissemination. Such screening has been successful for 
both colon [3] and cervical [4-6] cancers but results for 
breast cancer are less positive. Th  e widespread intro-
duction of population-based screening breast mammo-
graphy beginning in the mid 1980s resulted in a dramatic 
rise in the detection of stage 1 cancers as well as ductal 
carcinoma in situ. However, treatment of these patients 
has not resulted in the expected decrease in mortality, 
indicating that screening breast mammography misses 
critical lesions until after they have spread [7]. In fact, a 
recent study of over 40,000 Norwegian women with 
breast cancer showed that while screening was associated 
with a 10% reduction in the rate of death from breast 
cancer, only one-third of this improvement could be 
attri  buted directly to screening [8]. Balanced against this 
modest improvement in overall survival are the dangers 
of over-treatment with the attending therapy-linked 
morbidities. Th   is suggests that current screening strate-
gies are not detecting metastasis-prone lesions before 
metastatic spread has occurred and are detecting many 
lesions that will not progress to metastatic disease [9] or 
may even regress spontaneously [10]. Th   is may be due to 
lack of sensitivity to metastasis-prone breast cancers 
and/or progression during the interval between mammo-
graphic screenings. Th  us, improved screening strategies 
‘tuned’ speciﬁ  cally to detect metastasis-prone cancers are 
needed that are both more sensitive and suﬃ   ciently 
aﬀ  ordable for frequent use. In the unfortunate event that 
breast cancer does become metastatic, sensitive and 
subtype-speciﬁ   c disease detection strategies also may 
improve outcome by allowing subtype-speciﬁ  c, targeted 
therapy to begin when recurrent disease burden is 
smaller.
Global analyses of epigenomic, genomic, transcrip-
tional and proteomic (hereafter referred to as ‘omic’) 
changes that occur during progression to metastatic 
disease suggest candidate molecular markers that might 
be used as the basis for early detection assays. Th  ese 
changes occur during a multi-step process that allows 
sub  populations of the primary tumor and subsequent 
disseminated cells to escape their primary site and 
establish elsewhere [11]. Th   is process may include omic 
changes that enable mobilization, invasion, angiogenesis, 
epithelial-to-mesenchymal transition, vascular remodel-
ing, intravasation, immune evasion, extravasa  tion, and 
organ-speciﬁ   c colonization [12]. In cancer stem cell 
models, only a small persistent population of cells accrue 
the necessary mutations and are responsible for relapse 
and metastasis through a stem-cell-like process of diﬀ  er-
entiation and self-renewal [13]. In any case, omic studies 
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more metastasis-prone than others. For example, basal 
and luminal B tumors are more likely to progress to 
metastatic disease than luminal A tumors [14]. Th  is 
suggests that omic characteristics of metastasis-prone 
cancers can be used to develop strategies that will detect 
these aggressive cancers before signiﬁ  cant  cancer 
dissemi  nation has occurred.
Figure 1 suggests an omic-signature-based screening 
strategy that we believe will lead to earlier detection of 
metastasis-prone lesions and to high sensitivity detection 
of residual disease. An omic-signature refers to a 
molecular marker or panel of markers, useful for clinical 
decision making, determined by large-scale measurement 
at various omic levels, such as the genome (gene and 
regulatory sequences), epigenome (epigenetic modiﬁ    ca-
tions), transcriptome (RNA and gene expression), 
proteome (protein expression) and others. Th   is is a multi-
step screening process in which (a) low-cost blood-based 
assays of molecular signatures associated with metastasis-
prone disease are applied routinely to identify high-risk 
individuals, (b) more expensive but sensitive and speciﬁ  c 
anatomic assays are used to localize the lesions, and (c) 
molecular histopathological omic assays are used to 
identify and determine the molecular characteristics of 
even the smallest lesions. Th   e molecular information in 
individual tumors detected in this way can then be used 
to develop sensitive blood- or imaging-based ‘indi  vidu-
alized’ assays that might be used to enable early detection 
and treatment of recurrent disease.
Development of the strategies outlined above will 
require an extensive understanding of the molecular 
features of metastasis-prone breast cancers and of meta-
static disease in sites around the body. Breast cancers 
Figure 1. Predicting, detecting and monitoring metastatic breast cancer. The fi  gure portrays an omic-signature-based screening strategy for 
earlier detection of metastasis-prone lesions and high sensitivity detection of residual disease. This strategy is based on the premise that molecular 
features can be used to defi  ne breast cancer subtypes that are at high risk of progressing to metastatic disease. Molecular features associated with 
metastasis discovered through analysis of metastatic breast cancers are used to develop sensitive assays for disease. This involves a multi-step 
process in which low-cost blood-based assays of molecular signatures associated with metastasis-prone disease are applied routinely to identify 
high-risk individuals who are then screened using more expensive but sensitive and specifi  c anatomic assays followed by histopathological and 
omic assays to identify and characterize even the smallest lesions. The molecular information in individual tumors detected in this way can then 
be used to develop sensitive blood or imaging based ‘individualized’ assays for recurrent disease that might be used to guide early detection and 
treatment. *Image from [80] reprinted with permission from AAAS. All other images were obtained from Wikimedia Commons and are available 
under public domain, Creative Commons Attribution 3.0 Unported license [92], or Creative Commons Attribution-Share Alike 3.0 Unported license 
[93].
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liver, brain and other sites. Patterns of metastasis may be 
related to the molecular subtype of the tumor, with 
estrogen receptor (ER)-positive luminal-like cells spread-
ing preferentially to bone and ER-negative and basal-like 
tumors preferentially spreading to visceral organs [15,16]. 
Many genes have been identiﬁ  ed that act as oncogenes or 
tumor suppressor genes, allowing proliferation, resis-
tance to death signals, angiogenesis, altered cell adhesion 
and motility [17]. Changes in these genes mediate 
initiation and local progression of tumors and are 
prerequisites for metastasis. However, fewer genes have 
been identiﬁ  ed for the subsequent steps of ‘metastasis 
proper’ [18]. Genes that act as mediators of metastasis 
could be activated by many genetic and epigenetic 
mecha  nisms. Identifying metastasis-prone breast cancers, 
detecting residual metastatic cancer early and intervening 
eﬀ  ectively will likely require a detailed understanding of 
these speciﬁ  c changes.
Discovery of molecular features associated with meta-
stasis is increasingly possible through the application of 
advanced DNA, RNA and protein (omic) analysis tech-
nologies that reveal molecular features associated with 
these aspects of metastasis. Omic characterization of 
breast cancers has been underway for over a decade and 
is accelerating as a result of technological advances made 
during the course of international genome analysis 
eﬀ   orts. Initial developments were stimulated by the 
Human Genome Project [19,20] and have been acceler-
ated by work in Th  e Cancer Genome Atlas (TCGA) 
project [21] and in the International Cancer Genome 
Consortium (ICGC) [22]. We review here recent progress 
in elucidating the molecular features of metastatic breast 
cancer with the idea that this information can be used 
eventually to guide the development of assays suggested 
in Figure 1.
Prediction: signatures for metastasis
Molecular subtypes
Much of the eﬀ  ort to predict outcome in breast cancer 
(Table 1) has focused on the deﬁ  nition of molecular sub-
types, some of which have a high likelihood of progress-
ing to metastasis. Important markers such as ER, 
progesterone receptor and human epidermal growth 
factor receptor 2 (HER2) have long been used to predict 
response to treatment and deﬁ  ne important subclasses of 
breast cancer. Now, omic analyses are leading to multi-
gene expression signatures that further deﬁ  ne  breast 
cancer subtypes as basal, luminal A, luminal B, normal-
like [23] and claudin-low [24]. Th  ese distinct molecular 
subtypes display diﬀ   erent clinical behaviors and out-
comes. For example, patients with basal-like breast 
cancers are prone to more aggressive metastatic relapse 
whereas patients with luminal A cancers generally have 
good long-term outcome [23,25]. Th  e 50-gene PAM50 
signature was developed to standardize breast cancer 
subtyping using a 189 sample training set and was tested 
in 761 patients receiving no systemic therapy and 133 
patients treated with a taxane and anthracycline. Th  ese 
studies showed that the signature also added prognostic 
and predictive information to standard parameters for 
patients with breast cancer [26]. Other gene expression 
signatures, including the genomic grade index (GGI) [27] 
and molecular grade index (MGI) [28], are comple  men-
tary to histologic grade and have been used to identify 
additional distinct subtypes in ER-positive disease 
[28,29]. Th  e GGI can be used as a predictor of survival 
and has been associated with response to chemotherapy 
[30].
Prognostic signatures
Some gene signatures have been developed speciﬁ  cally to 
predict the risk of relapse, distant metastasis or response 
to speciﬁ  c therapies [31,32]. Th  ese include the 21-gene 
Oncotype Dx signature [33], the 70-gene MammaPrint 
signature [34] and the 76-gene Rotterdam signature [35]. 
Only a few genes are shared between these signatures 
and yet they perform comparably when applied to similar 
patient data and all improve risk assessment. Oncotype 
Dx is used to predict risk of relapse and response to 
treatment for patients with lymph-node-negative and 
ER-positive disease. Patients in the low-risk group have 
signiﬁ  cantly better outcome than those in the high-risk 
group and more patients can be put into this low-risk 
group (approximately 50%) than with traditional risk 
assessment methods (for example, St Gallen criteria) 
[33]. Oncotype recurrence score is also predictive of 
degree of beneﬁ  t from adjuvant chemotherapy [36]. Th  e 
Mammaprint signature was originally validated in a 
cohort of 234 premenopausal women with no systemic 
therapy [37]. Patients in the high-risk group had 
signiﬁ  cantly lower rates of overall 10-year survival and 
distant metastasis-free survival. Mammaprint’s utility has 
since been further demonstrated in post-menopausal 
women [38]. Mammaprint has been shown to be a useful 
predictor of metastasis even in tumors otherwise thought 
to have good prognosis [39]. Most recently, studies have 
shown predictive value for response to both neoadjuvant 
[40] and adjuvant [41] chemotherapy. A cost-beneﬁ  t 
study showed that Mammaprint improves quality-adjusted 
survival and will be cost-eﬀ  ective compared to St Gallen 
guidelines and the Adjuvant Online Software for assess-
ing prognosis [42]. Th  e 76-gene Rotterdam signature is 
particularly relevant to detection of metastasis-prone 
cancers since it was developed to predict metastatic 
spread in lymph-node-negative patients [35]. It was 
originally developed using a training set of 115 lymph-
node-negative patients and tested in a test set of 171 
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ﬁ  ed patients at high risk of developing distant metastases 
within 5 years. It was validated subsequently in a multi-
center evaluation of an additional 171 lymph-node-
negative patients [43]
Signatures predicting response to specifi  c agents
Distinct from the purely prognostic signatures discussed 
above are signatures under development for the predic-
tion of response to speciﬁ  c agents. Oakman and colleagues 
[31] have recently reviewed in detail the evidence for 
single gene markers of drug response. Th   ese include the 
use of HER2 and TOP2A ampliﬁ  cation/expression  to 
predict anthracycline response; HER2, protein tau, and 
P53 to predict response to taxanes; and BRCA1 or the 
related basal-signature to predict response to DNA 
damaging agents. Others have reviewed multi-gene 
signa  tures for predicting sensitivity to speciﬁ  c  agents 
[44,45]. Loi and colleagues [46] developed a 181-gene 
signature that separates patients based on outcome after 
adjuvant tamoxifen therapy. An advantage of this signa-
ture is that it was clustered in 13 clusters of highly 
correlated genes from which numerous diﬀ  erent 13-gene 
signatures were evaluated and found to have nearly the 
same performance as the complete signature. Th  e SET 
index, a set of 165 genes co-expressed with ER, was 
shown to predict survival beneﬁ  t from adjuvant endo-
crine therapy [47]. Th   is signature was not prognostic in 
untreated cohorts, indicating that it may speciﬁ  cally 
predict treatment beneﬁ   t rather than simply correlate 
with better outcomes as do some others. Th  e  DLDA-30 
signature has been shown to be predictive of pathologic 
complete response after pre-operative treatment with 
paclitaxel and a combination of ﬂ  uorouracil, doxorubicin, 
and cyclophosphamide (T/FAC) with high sensitivity 
[48]. Validation studies have conﬁ   rmed the ability of 
DLDA-30 to identify patients with higher than average 
sensitivity to T/FAC chemotherapy [49]. However, its 
per  formance was not signiﬁ   cantly better than clinical 
variable-based predictors, raising an important metric 
for success of such signatures. Similar eﬀ  orts are under-
way to develop multi-gene predictors of response to 
taxanes/anthracyclines [50], dasatinib [51], and others.
Transcriptional signatures for metastasis and related 
biological themes
Other signatures may provide more direct information 
about the biology of metastasis. For example, several 
gene expression signatures correlated with genomic 
instability have been found to be independent predictors 
Table 1. Selected expression signatures potentially useful for predicting metastasis-prone breast cancer
Signature Description
Molecular subtype   Breast tumors can be partitioned into distinct molecular subtypes such as basal-like, luminal, HER2-positive, normal-like, 
[23,24]  claudin-low and others with distinctly diff  erent clinical behaviors and outcomes using global or multi-gene expression signatures
PAM50 [26]  A 50-gene signature developed to standardize breast cancer subtyping. This study showed that the signature added prognostic 
  and predictive information to standard parameters for patients with breast cancer
Histologic grade   Gene expression signatures correlated with histologic grade, such as the genomic grade index (GGI) and molecular grade index
(GGI [27]; MGI [28])  (MGI), can be complementary to histologic grade and used to predict survival and response to chemotherapy
Oncotype DX   A 21-gene signature initially developed to determine risk of relapse and response to chemotherapy in ER-positive and
(Genomic Health) [33]  lymph-node-negative patients 
Mammaprint   A 70-gene signature initially developed for pre-menopausal women but subsequently also found useful for post-menopausal
(Agendia) [34]  women for prediction of risk of metastasis and chemotherapy response
Rotterdam (Veridex,   A 76-gene signature that predicts risk of distant metastasis in lymph-node-negative (ER-positive or ER-negative) patients
Johnson & Johnson) [35] 
SET index [47]  A 165-gene signature correlated with ER that predicts response to adjuvant endocrine therapy independent of general 
 prognosis
DLDA30 [49]  A 30-gene predictor of sensitivity to T/FAC chemotherapy
Genomic instability   Several expression signatures correlated with measures of genomic instability have been developed and determined to be
[52-54]  predictors of poor prognosis and metastasis
Wound [55]  A 512-gene signature that characterizes the response of fi  broblasts to serum and is predictive of metastasis and death
Hypoxia [56]  A 253-gene signature characterizing hypoxia response that is predictive of clinical outcomes in breast and ovarian cancers
Invasion [57]  A 186-gene signature developed by comparing tumorigenic and non-tumorigenic breast cancer cells as defi  ned by expression of 
  cell-surface proteins CD44 and CD24 or epithelial-specifi  c antigen and CD10; associated with overall survival and metastasis-free 
 survival
Lung-specifi  c   A 54-gene signature representing the diff  erences between a parental breast cancer cell line and a derived line selected for ability to
metastasis [58]  metastasize specifi  cally to lung. Individual genes and selected combinations were shown to promote lung metastasis when 
  over-expressed and the signature overall distinguishes between patients with high and low risk for lung metastasis
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2.
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‘wound signature’ associated with the response of 
ﬁ  broblasts to serum across a wide range of anatomic sites 
[55] also predicts increased risk of metastasis and death 
in breast cancer. Other signatures with predictive poten-
tial for metastatic phenotype include a 253-gene ‘hypoxia’ 
signature [56] and a 186-gene ‘invasion’ signature [57]. A 
‘lung metastasis’ signature [58] is even more directly 
related to the metastatic process. Serial in vivo selection 
of a breast cancer cell line (MDA-MB-231) produced a 
derivative line (LM2) that metastasized readily to the 
lung in mice. Comparison of the derivative line to the 
parental line identiﬁ  ed a set of 54 diﬀ  erentially expressed 
genes. Over-expression of nine of these genes, singly and 
in combination, consistently increased aggressive meta-
static activity and some combinations completely re-
capitu  lated aggressiveness of the LM2 line. Bone meta-
static activity was not increased, conﬁ  rming the tissue-
speciﬁ   c functions of these genes. Down-regulation by 
RNA interference in LM2 cells decreased metastatic 
activity by more than ten-fold. Th  e 54-gene signature 
distinguished between patients with high risk and low 
risk of lung metastasis. However, only 18 of the 54 genes 
were found to be expressed in primary tumors of breast 
cancer patients. Th  is suggests that detection strategies 
for metastasis-prone cancers might best focus on genes 
activated at early stages that are directly involved in 
metastasis.
Metastasis-related genomic events
Detection strategies for metastasis-prone breast cancers 
may be improved by using genomic information, includ-
ing copy number, promoter methylation and mutations. 
Massively parallel sequencing (MPS) projects, including 
the TCGA and the ICGC, are provid  ing these data 
[21,22]. In breast cancer, mutations in BRCA1 and 
BRCA2 are well established as important in the relatively 
rare familial breast cancers [59]. Other mutated genes in 
breast cancer reported in the Catalogue of Somatic 
Mutations in Cancer (COSMIC) database [60] include 
PIK3CA (25% [61]), TP53 and CDH1 (22%), PTEN (6%), 
AKT1 (5%) and numerous mutations that occur at 
frequencies <5%. Th   e roles of these mutations in 
metastatic progression are mostly unknown, although 
some are early events that may be useful as markers of 
residual disease. Importantly, several of these mutations, 
including in TP53 [62] and BRCA1 [14], are preferentially 
associated with the metastasis-prone basal subtype.
Early detection strategies based on genomic aberrations 
will be inﬂ   uenced by when these aberrations occur 
during evolution and metastasis. Th  e mutational land-
scape in metastatic breast cancer has only just begun to 
be elucidated with two key papers recently published. 
One sequenced DNA from a basal-like primary breast 
tumor, subsequent brain metastasis, peripheral blood 
and a xenograft derived from the primary [63]. Th  e 
second sequenced an ER-positive lobular breast tumor 
and subsequent pleural eﬀ  usion [64]. Th  e pleural eﬀ  u-
sion, collected 9 years after the primary tumor, contained 
32 somatic non-synonymous coding mutations, of which 
19 were unique to the metastasis, 6 enriched and only 5 
prevalent in the primary. No somatic structural changes 
were identiﬁ   ed. In contrast, the brain metastasis, 
collected less than a year after primary surgery, contained 
50 mutations and 41 structural variations, of which only 
two mutations and a large deletion were unique to the 
metastasis. Copy number alterations were found to be 
both increased in number and expanded in metastatic 
tissue relative to the primary. It is possible that diﬀ  erences 
in the numbers of metastasis-speciﬁ  c mutations found 
between the two studies have as much to do with the 
intrinsic subtypes of the tumors as with timing. Larger 
studies will be needed to identify recurrent sequence 
changes relevant to the metastatic process and to 
determine when these changes occur. If possible, early 
detection methods should focus on aberrations present 
in the primary tumor that predispose to metastasis. 
Projects such as TCGA and ICGC are now providing a 
wealth of omic information on primary breast tumors 
[21,22]. However, analyses of primary/metastasis pairs 
will take longer as these samples are diﬃ   cult to acquire 
and will require special eﬀ  ort. Eﬀ  orts to chronologically 
order genomic aberrations may be facilitated by the 
development of strategies based on the structure of the 
genome in a single sample rather than by analyzing serial 
samples.
Detection: the metastatic needle in the haystack
It is likely that no single molecular feature will identify all 
metastatic lesions. Indeed, the signatures for metastatic 
basal and luminal subtype cancers may be completely 
diﬀ  erent. In addition, stochastic genetic, environmental 
and microenvironmental factors may inﬂ  uence  the 
molecular features of metastatic cancers. Th  is suggests 
that assays for early detection of metastasis-prone 
cancers must assess multiple omic features. Ultimately, a 
tiered approach such as that depicted in Figure  1 will 
likely be needed, with blood-based tests used to identify 
patients with molecular features putting them at high 
risk of carrying metastasis-prone lesions followed by 
sensitive molecular imaging for anatomic localization.
Blood-based detection
Proteomic methods
Plasma biomarkers are ideal for disease detection 
because they can be measured inexpensively for the 
general population to enable early disease detection. 
However, discovery of highly speciﬁ  c tumor biomarkers 
Griffi   th and Gray Breast Cancer Research 2011, 13:230 
http://breast-cancer-research.com/content/13/6/230
Page 5 of 11in the plasma is hampered by interference from a small 
number of highly abundant and absorbent proteins (for 
example, albumin) that make up 99% of the total protein 
mass in plasma [65]. For this reason, a prioritization step 
will be required to predict which biomarkers are most 
likely to be useful for blood-based screening so that 
enrichment strategies can be developed for these markers 
(see Box 1 for sample criteria). Candidates must then be 
validated in plasma-based assays. Traditional assays such 
as ELISA typically require expensive and time-consuming 
development for each potential candidate and thus 
represent an important bottleneck in the discovery pipe-
line [65]. New high-throughput methods are being 
developed to overcome this bottleneck, particularly 
targeted mass spectrometry (MS) methods such as 
selected reaction monitoring MS (SRM-MS). Th  ese 
approaches are similar to standard MS but can be ‘tuned’ 
to look for speciﬁ   c peptides using knowledge of the 
expected m/z based on in silico digestion of candidate 
proteins (for example, those identiﬁ  ed as associated with 
metastasis). Spiking known quantities of isotope-labeled 
proteins of interest allows quantiﬁ  cation of the endoge-
nous protein. Sensitivity can be further improved by 
enrich  ment steps with aﬃ   nity reagents, allowing detec-
tion of protein biomarkers down to 100 pg/ml. A further 
derivation of the method, multiple reaction monitoring 
MS (MRM-MS), is achieved by monitoring several 
diﬀ  erent SRM transitions within one MS run, allowing 
simultaneous measurement of multiple proteins or 
protein isoforms [66]. Th  is method allows multiple low 
abundance proteins to be quantiﬁ  ed simultaneously with 
excellent accuracy and reproducibility [67]. MRM-MS 
can even be used to measure phosphorylation 
stoichiometry and recent proof of principle experiments 
have measured both phosphorylation and total protein 
abundance of critical breast cancer biomarkers such as 
ER and HER2 [68]. Few studies have yet applied these 
methods speciﬁ  cally to breast cancer metastasis. In one 
example, however, liquid chromatography MS was used 
to compare plasma membrane protein abundances 
between metastatic and non-metastatic breast cancer 
cells in a mouse model. A total of 1,919 proteins were 
detected and of these, 13 were diﬀ  erentially expressed. 
Subsequent validation in clinical breast cancer biopsies 
found a signiﬁ  cant association between high CD73 or 
integrin β1 and poor outcome [69]. Mining of the 
metastatic proteome will likely be a critical step in the 
development of blood-based biomarkers for both 
prediction of metastatic outcome and monitoring of 
residual disease and treatment response.
Circulating tumor cells and disseminated tumor cells
Disseminated tumor cells (DTCs) in the bone marrow or 
lymph nodes or circulating tumor cells (CTCs) in the 
blood represent other opportunities for early disease 
detec  tion or recurrence monitoring. Detection typically 
involves an initial enrichment step, such as gradient 
centri  fugation or immunomagnetic separation, used 
together with either positive selection for CTCs (for 
example, by epithelium-speciﬁ  c antibodies such as anti-
epithelial cell adhesion molecule (EpCAM)) or by 
negative depletion of hematopoietic cells (for example, by 
antibodies against CD45) [70]. Diﬀ  eren  tiation of DTCs/
CTCs is then performed by immuno  cyto  chemistry or 
PCR-based techniques [71,72]. To date, most commercial 
systems are based on immunological approaches. Th  ese 
have the advantage of detecting DTCs/CTCs and also 
providing metrics such as cell size, shape and staining 
patterns. Primary issues with these assays are relatively low 
sensitivity and the fact that the epithelial antigens typically 
used for detection may not be expressed on all tumor cells 
[73]. Alternative antibodies such as anti-cytokeratins can 
increase sensitivity [74] but again may vary between 
tumors. Molecular PCR-based approaches oﬀ  er increased 
sensitivity but are dependent on detection of known 
mutations, ampliﬁ  cations or methylation patterns.
Several studies have shown an association between the 
presence of DTCs in the bone marrow and metastatic 
relapse in breast cancer [72]. Approximately 30% of 
women with primary breast cancer harbor DTCs in their 
bone marrow even in the absence of overt metastasis and 
these patients have worse prognosis than those without 
Box 1. Criteria to select markers for blood-based 
screening
Association with metastasis: In order to be predictive markers 
for metastasis, the marker must be somehow specifi  c to 
metastatic cells. This specifi  city could be a quantitative diff  erence 
(for example, increase in measurable transcript, protein, and so 
on) or a qualitative diff  erence (alternative splice form, fusion 
product, mutation, post-translational modifi  cation, and so on).
Mechanistic: ideal markers would be causally related to some 
aspect of metastatic progression, therefore serving both as 
biomarkers and potential therapeutic targets.
Highly expressed: ideal markers will be highly expressed in 
metastatic lesions making detection easier.
Readily assayed and measurable: An assay must exist that can 
(preferably) quantitatively measure the marker. Also, the marker 
must be accessible to the assay in the blood. Thus, biomarkers 
that are located on the cell surface or secreted are favored.
Stable against degradation: Markers should be stable in 
the blood so that infrequent assays will be able to detect 
their presence. Based purely on stability, this might argue for 
prioritization of DNA over protein and protein over RNA.
Multi-gene, multi-assay: Individual markers are not likely to be 
suffi   cient. Accurate and sensitive detection may require multi-
marker assays and separate assays for diff  erent disease subtypes.
Griffi   th and Gray Breast Cancer Research 2011, 13:230 
http://breast-cancer-research.com/content/13/6/230
Page 6 of 11DTCs detected [75]. Th  e presence of extensive bone 
metastases has been associated with increased CTC 
numbers in metastatic breast cancer [76]. A prospective 
multicenter trial of patients with metastatic breast cancer 
found that about half of all patients had detectable CTCs 
using the CellSearch® assay and about 40% were positive 
using AdnaTest BreastCancer™ [77]. More interestingly, 
up to half of patients with HER2-negative primary 
tumors had HER2-positive CTCs. Th  is suggests that 
HER2 status can change during breast cancer progression 
or relapse and raises the possibility that monitoring of 
CTCs for such markers could inform targeted treatment 
of metastasis. Th   ere remains, however, a troublingly poor 
concordance between CTC assay methods. Development 
of consistent CTC detection methods and standard 
HER2 (and other biomarker) assessment methods is still 
needed. Another challenge is that CTCs can lie dormant 
for years and have been detected in patients with 
metastasis-free survival over 20 years after primary 
diagnosis [78]. Th   us, simple detection of CTCs alone may 
not be suﬃ   cient to identify clinically important meta-
static disease or determine the correct treatment. Indeed, 
studies have shown that only a subset of DTCs/CTCs 
detected are viable and that many are simply terminal or 
dead tumor cells shed from the primary or metastasis 
and do not necessarily directly represent metastatic cells 
(reviewed in [79]).
Circulating tumor DNA
MPS also holds the promise of personalized and sensitive 
detection of recurrent disease by measuring the charac-
teristics of circulating tumor DNA. Leary and colleagues 
[80] report the use of MPS to screen primary tumors for 
patient-speciﬁ   c structural rearrangements followed by 
PCR-based assessment of plasma DNA using primers 
that ﬂ   ank the aberration breakpoints. Th  is method, 
termed ‘personalized analysis of rearranged ends’ 
(PARE), identiﬁ  ed tumor-speciﬁ  c biomarkers that can be 
used to monitor response to therapy, assess residual 
disease and/or monitor for relapse. Two breast (along 
with four colorectal) tumors were analyzed using this 
approach. At least four somatic rearrangements were 
conﬁ   rmed in each tumor (ﬁ   ve and ﬁ   fteen in the two 
breast tumors). All were unique with no recurring re-
arrangements between any of the six tumors. Plasma 
blood from two of the colorectal cancer patients was 
assayed by digital PCR analysis and the presence of one 
rearrangement each was successfully detected. For one 
patient, blood was available at several time points, 
allowing the tracking of mutant DNA fraction as it 
sharply decreased after surgery, rebounded and then 
decreased again after chemotherapy and removal of 
metastatic lesions. A small non-zero detection level 
remained after all treatments, consistent with known 
residual metastatic disease in the remaining left lobe of 
the liver. A recent survey of 24 breast cancer genomes by 
MPS found substantial variation in the number of 
observed rearrangements from 1 to 231 (median 38) in 
primaries and 58 to 245 (median 101) in cell lines [81]. 
Th   is demonstrates the general potential for personalized 
detection and monitoring of disease by a sensitive and 
quantitative method. Such methods could ultimately be 
complemented by equally personalized therapeutic 
approaches. Recently, the ﬁ  rst example of clinical appli-
cation of whole genome/transcriptome analysis described 
a MPS analysis of a rare adenocarcinoma of the tongue 
and subsequent metastases to the lung and skin [82]. Th  e 
observation of ampliﬁ  cation and up-regulation of RET 
and downstream pathway members was used to inform 
clinical selection of RET inhibitor therapy with some 
apparent success. However, such cases remain anecdotal.
Anatomic detection
Detection of breast cancer by molecular imaging 
techniques has been reviewed extensively elsewhere [83] 
but will be discussed brieﬂ  y here. Proton magnetic reso-
nance spectroscopy (MRS) is one of the most established 
techniques. While MRI uses the signal from hydrogen 
protons to form anatomic images, proton MRS uses this 
information to determine the concentration of metabo-
lites. For example, MRS focused on choline metabolites 
can be used to detect malignant breast disease at a 
sensitivity of 80% and speciﬁ  city of 100% [84]. Imaging 
methods that focus speciﬁ  cally on detecting metastasis 
are less common but still plentiful. A recent meta-
analysis compared ultrasound, computed tomography, 
MRI, scintimammography and positron emission tomo-
graphy (PET) for their abilities to detect breast cancer 
recurrence or metastasis [85]. For the 42 studies included, 
ultrasound and MRI had the highest speciﬁ  city (0.962 
and 0.929) and MRI and PET had the best sensitivity 
(0.950 and 0.953). Th   ey concluded that MRI was the most 
useful supplement to standard surveillance techniques 
but recommended ﬂ   uorodeoxyglucose (FDG)-PET for 
cases where MRI was indeterminate or unavailable. It 
should be noted that the pooled detection accuracies 
reported are likely overly optimistic. In most cases the 
reason for performing imaging was suspicion of recur-
rence from other indicators; thus, the population was 
enriched for recurrences. Th   e studies also included local 
recurrences, which are easier to detect than distant 
micro  metastasis. In any case, this analysis demonstrated 
a high potential accuracy for detection of breast meta-
stasis by several imaging modalities.
Th   e metastasis-prone triple-negative subtype of breast 
cancer can be detected with high sensitivity using FDG-
PET and shows a distinctly enhanced FDG uptake 
compared to other subtypes [86]. Breast-speciﬁ  c gamma 
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show promise in ﬁ   nding small invasive cancers with 
reported sensitivities of 79 to 96% [83]. MRI can detect 
lymph node metastasis with excellent speciﬁ  city (100%) 
and positive predictive value (100%) [87]. Recent reports 
have demonstrated that whole-body MRI can be per-
formed in approximately 1 hour and provide ‘diagnos-
tically adequate’ detection of breast cancer metastases 
[88]. Th   e study looked at 19 breast cancer patients with 
known metastases using whole-body, Dixon-based multi-
sequence and multiplanar MRI. Th   e procedure was well 
tolerated by 18 out of 19 patients, took only 69 ± 5 minutes 
of patient time, and image quality was graded as good to 
excellent by radiologists. A number of diﬀ  erent histolo-
gically proven metastases were detected. It remains to be 
seen whether the method can detect de novo metastasis 
and whether such detection can actually improve out-
comes. However, applying these techniques for assess  ment 
of patients at high risk of metastatic disease indicated by 
blood-based screening methods seems promising.
While these imaging methods are getting better at 
detecting malignant from benign or normal tissues, more 
work is needed for the detection of micrometastases. 
Sensitive detection methods targeting the molecular 
features of metastasis revealed by omic analyses are 
needed. Biomarkers from metastatic signatures may 
allow the development of targeted contrast reagents to 
improve imaging of breast metastasis. Targeted contrast 
reagents are created by the conjugation of imaging tracer 
molecules (such as quantum dots, radiotracers, ﬂ  uoro-
phores, and so on) with aﬃ   nity-based targeting mole-
cules (such as nucleic acids, proteins, antibodies, anti-
body fragments, or engineered aﬃ   bodies) that target a 
biological molecule of interest (reviewed in [89]). In 
principal, the most attractive features for this purpose are 
cell surface proteins that are uniquely represented or 
particularly highly expressed in the metastasis-prone 
cells. Such agents can be used in conjunction with MRI, 
PET, X-ray, transmission electron microscopy and other 
imaging modalities. For example, in mice xenografts, a 
targeted contrast reagent composed of 18F radiotracer 
and a HER2 aﬃ   body was recently shown to allow in vivo 
monitoring of HER2 expression levels by PET [90]. 
Similar metastasis-speciﬁ  c agents might someday allow 
whole-body sensitive detection and monitoring of meta-
static lesions. Work in this area is still in the early stages 
of development but should be eﬀ  ectively guided by the 
omic analyses described above that are revealing highly 
expressed cell surface molecules that are associated with 
metastasis and/or reduced survival duration.
Conclusion
Metastatic disease is a major challenge for breast cancer 
management. Improvements in outcome may come either 
from improving treatment strategies or by identifying 
and treating metastasis-prone breast cancers before 
meta  static dissemination has occurred. Th  e latter stra-
tegy is promising since modern omic analysis procedures 
are now providing molecular descriptors of metastasis-
prone cancers. Th  is information should guide develop-
ment of the required sensitive blood- and imaging-based 
detection strategies. Sensitive, subtype-speciﬁ  c  tumor 
detection strategies also may allow earlier detection and 
treatment of recurrent disease. Methods for earlier 
detection of recurrent disease already exist, but to date 
there has been no identiﬁ  ed beneﬁ  t of monitoring for 
distant relapse since metastatic disease remains essen-
tially uncurable. In fact, American Society of Clinical 
Oncology (ASCO) published guidelines for breast cancer 
follow-up and management do not include any recom-
mendations for detection/screening beyond history and 
physical examination [91]. However, detection strategies 
that identify molecular features that suggest therapies 
likely to be eﬀ   ective in the screened individual may 
change the currently dismal situation.
Abbreviations
CTC, circulating tumor cell; DTC, disseminated tumor cell; ELISA, enzyme-
linked immunosorbent assay; ER, estrogen receptor; FDG, fl  uorodeoxyglucose; 
GGI, genomic grade index; HER2, human epidermal growth factor receptor 2; 
ICGC, International Cancer Genome Consortium; MGI, molecular grade index; 
MPS, massively parallel sequencing; MRI, magnetic resonance imaging; MRM, 
multiple reaction monitoring; MRS, magnetic resonance spectroscopy; MS, 
mass spectrometry; PCR, polymerase chain reaction; PET, positron emission 
tomography; SRM, selected reaction monitoring; TCGA, The Cancer Genome 
Atlas.
Competing interests
Joe Gray serves on Scientifi  c Advisory Boards for Agendia, Cepheid, KromaTiD 
and New Leaf ventures.
Acknowledgments
This work was supported by the Director, Offi   ce of Science, Offi   ce of Biological 
and Environmental Research, of the US Department of Energy under contract 
number DE-AC02-05CH11231, by the Department of the Army, award 
W81XWH-07-1-0663, the National Institutes of Health, National Cancer 
Institute grants P50 CA 58207, the U24 CA 126477, and the Canadian Institutes 
of Health Research. The content of the information does not necessarily refl  ect 
the position or the policy of the Government, and no offi   cial endorsement 
should be inferred.
Author details
1Lawrence Berkeley National Laboratory, Life Sciences Division, Cancer and 
DNA Damage Responses, One Cyclotron Road, Berkeley, CA 94720, USA. 
2Oregon Health and Science University, Biomedical Engineering Department, 
3303 SW Bond Ave, Portland, OR 97239, USA.
Published: 8 December 2011
References
1.  Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, 
Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, 
Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK: SEER Cancer Statistics Review, 
1975-2007. Bethesda, MD: National Cancer Institute; 2010.
2.  Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, 
Anderson G, Hartwell L: The case for early detection. Nat Rev Cancer 2003, 
3:243-252.
3.  Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, 
Anderson RN, Edwards BK: Annual report to the nation on the status of 
Griffi   th and Gray Breast Cancer Research 2011, 13:230 
http://breast-cancer-research.com/content/13/6/230
Page 8 of 11cancer, 1975-2001, with a special feature regarding survival. Cancer 2004, 
101:3-27.
4.  Laara E, Day NE, Hakama M: Trends in mortality from cervical cancer in the 
Nordic countries: association with organised screening programmes. 
Lancet 1987, 1:1247-1249.
5.  Johannesson G, Geirsson G, Day N: The eff  ect of mass screening in Iceland, 
1965-74, on the incidence and mortality of cervical carcinoma. Int J Cancer 
1978, 21:418-425.
6. Sigurdsson  K:  Eff  ect of organized screening on the risk of cervical cancer. 
Evaluation of screening activity in Iceland, 1964-1991. Int J Cancer 1993, 
54:563-570.
7.  Tabar L, Fagerberg G, Duff  y SW, Day NE, Gad A, Grontoft O: Update of the 
Swedish two-county program of mammographic screening for breast 
cancer. Radiol Clin North Am 1992, 30:187-210.
8.  Kalager M, Zelen M, Langmark F, Adami HO: Eff  ect of screening 
mammography on breast-cancer mortality in Norway. N Engl J Med 2010, 
363:1203-1210.
9.  Jorgensen KJ, Gotzsche PC: Overdiagnosis in publicly organised 
mammography screening programmes: systematic review of incidence 
trends. BMJ 2009, 339:b2587.
10.  Zahl PH, Maehlen J, Welch HG: The natural history of invasive breast 
cancers detected by screening mammography. Arch Intern Med 2008, 
168:2311-2316.
11.  Hunter KW, Crawford NP, Alsarraj J: Mechanisms of metastasis. Breast Cancer 
Res 2008, 10 Suppl 1:S2.
12.  Chiang AC, Massague J: Molecular basis of metastasis. N Engl J Med 2008, 
359:2814-2823.
13.  Kraljevic Pavelic S, Sedic M, Bosnjak H, Spaventi S, Pavelic K: Metastasis: new 
perspectives on an old problem. Mol Cancer 2011, 10:22.
14.  Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, 
Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-
Dale AL, Botstein D: Repeated observation of breast tumor subtypes in 
independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 
100:8418-8423.
15.  Luck AA, Evans AJ, Green AR, Rakha EA, Paish C, Ellis IO: The infl  uence of 
basal phenotype on the metastatic pattern of breast cancer. Clin Oncol 
(R Coll Radiol) 2008, 20:40-45.
16.  Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen 
TO, Gelmon K: Metastatic behavior of breast cancer subtypes. J Clin Oncol 
2010, 28:3271-3277.
17.  Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, 
Stratton MR: A census of human cancer genes. Nat Rev Cancer 2004, 
4:177-183.
18.  Nguyen DX, Massague J: Genetic determinants of cancer metastasis. Nat 
Rev Genet 2007, 8:341-352.
19.  Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, 
Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland 
J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, 
Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, 
Sougnez C, et al.: Initial sequencing and analysis of the human genome. 
Nature 2001, 409:860-921.
20.  Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, 
Yandell M, Evans CA, Holt RA, Gocayne JD, Amanatides P, Ballew RM, Huson 
DH, Wortman JR, Zhang Q, Kodira CD, Zheng XH, Chen L, Skupski M, 
Subramanian G, Thomas PD, Zhang J, Gabor Miklos GL, Nelson C, Broder S, 
Clark AG, Nadeau J, McKusick VA, Zinder N, et al.: The sequence of the 
human genome. Science 2001, 291:1304-1351.
21.  The Cancer Genome Atlas Research Network: Comprehensive genomic 
characterization defi  nes human glioblastoma genes and core pathways. 
Nature 2008, 455:1061-1068.
22.  International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, 
Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, 
Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, 
Kusada J, Lane DP, Laplace F, Youyong L, Nettekoven G, Ozenberger B, 
Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, et al.: 
International network of cancer genome projects. Nature 2010, 
464:993-998.
23.  Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, 
van de Rijn M, Jeff  rey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, 
Eystein Lønning P, Børresen-Dale AL: Gene expression patterns of breast 
carcinomas distinguish tumor subclasses with clinical implications. Proc 
Natl Acad Sci U S A 2001, 98:10869-10874.
24.  Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen 
KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov 
AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, 
Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou 
CM: Identifi  cation of conserved gene expression features between murine 
mammary carcinoma models and human breast tumors. Genome Biol 2007, 
8:R76.
25.  Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeff  rey SS, Rees CA, Pollack JR, 
Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu 
SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits 
of human breast tumours. Nature 2000, 406:747-752.
26.  Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, 
Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, 
Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS: Supervised 
risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 
2009, 27:1160-1167.
27.  Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, 
Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten 
D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M: Gene 
expression profi  ling in breast cancer: understanding the molecular basis 
of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 
98:262-272.
28.  Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris A, Goss P, 
Sotiriou C, Erlander M, Sgroi D: A fi  ve-gene molecular grade index and 
HOXB13:IL17BR are complementary prognostic factors in early stage 
breast cancer. Clin Cancer Res 2008, 14:2601-2608.
29.  Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, 
Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, 
Piccart MJ, Sotiriou C: Defi  nition of clinically distinct molecular subtypes in 
estrogen receptor-positive breast carcinomas through genomic grade. 
J Clin Oncol 2007, 25:1239-1246.
30.  Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer 
H, Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, Pusztai L: Genomic grade 
index is associated with response to chemotherapy in patients with breast 
cancer. J Clin Oncol 2009, 27:3185-3191.
31.  Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A: Recent 
advances in systemic therapy: new diagnostics and biological predictors 
of outcome in early breast cancer. Breast Cancer Res 2009, 11:205.
32.  Kim C, Paik S: Gene-expression-based prognostic assays for breast cancer. 
Nat Rev Clin Oncol 2010, 7:340-347.
33.  Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, 
Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: 
A multigene assay to predict recurrence of tamoxifen-treated, node-
negative breast cancer. N Engl J Med 2004, 351:2817-2826.
34.  van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van 
der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, 
Linsley PS, Bernards R, Friend SH: Gene expression profi  ling predicts clinical 
outcome of breast cancer. Nature 2002, 415:530-536.
35.  Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, 
Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, 
Foekens JA: Gene-expression profi  les to predict distant metastasis of 
lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
36.  Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, 
Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N: Gene 
expression and benefi  t of chemotherapy in women with node-negative, 
estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734.
37.  van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, 
Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, 
Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, 
Bernards R: A gene-expression signature as a predictor of survival in breast 
cancer. N Engl J Med 2002, 347:1999-2009.
38.  Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, 
Floore A, Rutgers EJ, van ‘t Veer LJ: The 70-gene prognosis signature 
predicts early metastasis in breast cancer patients between 55 and 70 
years of age. Ann Oncol 2010, 21:717-722.
39.  Mook S, Knauer M, Bueno-de-Mesquita JM, Retel VP, Wesseling J, Linn SC, 
Van’t Veer LJ, Rutgers EJ: Metastatic potential of T1 breast cancer can be 
predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 2010, 
17:1406-1413.
40.  Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ, 
Griffi   th and Gray Breast Cancer Research 2011, 13:230 
http://breast-cancer-research.com/content/13/6/230
Page 9 of 11Vrancken Peeters MJ, van Tinteren H, Van’t Veer LJ, Rodenhuis S: The 70-gene 
signature as a response predictor for neoadjuvant chemotherapy in 
breast cancer. Breast Cancer Res Treat 2010, 119:551-558.
41.  Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, 
Koornstra RH, Bueno-de-Mesquita JM, Linn SC, van ‘t Veer LJ: The predictive 
value of the 70-gene signature for adjuvant chemotherapy in early breast 
cancer. Breast Cancer Res Treat 2010, 120:655-661.
42.  Retel VP, Joore MA, Knauer M, Linn SC, Hauptmann M, Harten WH: Cost-
eff  ectiveness of the 70-gene signature versus St. Gallen guidelines and 
Adjuvant Online for early breast cancer. Eur J Cancer 2010, 46:1382-1391.
43.  Foekens JA, Atkins D, Zhang Y, Sweep FC, Harbeck N, Paradiso A, Cufer T, 
Sieuwerts AM, Talantov D, Span PN, Tjan-Heijnen VC, Zito AF, Specht K, 
Hoefl  er H, Golouh R, Schittulli F, Schmitt M, Beex LV, Klijn JG, Wang Y: 
Multicenter validation of a gene expression-based prognostic signature in 
lymph node-negative primary breast cancer. J Clin Oncol 2006, 
24:1665-1671.
44.  Tordai A, Liedtke C, Pusztai L: Metastatic gene signatures and emerging 
novel prognostic tests in the management of early stage breast cancer. 
Clin Exp Metastasis 2009, 26:625-632.
45.  Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J 
Med 2009, 360:790-800.
46.  Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis 
P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, 
Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C: Predicting prognosis using 
molecular profi  ling in estrogen receptor-positive breast cancer treated 
with tamoxifen. BMC Genomics 2008, 9:239.
47.  Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, 
Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, 
Valero V, Booser DJ, Hortobagyi GN, Pusztai L: Genomic index of sensitivity 
to endocrine therapy for breast cancer. J Clin Oncol 2010, 28:4111-4119.
48.  Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, 
Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, 
Gómez HL, Hortobagyi GN, Pusztai L: Pharmacogenomic predictor of 
sensitivity to preoperative chemotherapy with paclitaxel and fl  uorouracil, 
doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006, 
24:4236-4244.
49.  Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-
Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi 
GN, Hess KR, Symmans WF, Pusztai L: Evaluation of a 30-gene paclitaxel, 
fl  uorouracil, doxorubicin, and cyclophosphamide chemotherapy response 
predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 
2010, 16:5351-5361.
50.  Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes 
F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, 
Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, 
Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O’Shaughnessy J, 
Hortobagyi GN, Symmans WF: A genomic predictor of response and 
survival following taxane-anthracycline chemotherapy for invasive breast 
cancer. JAMA 2011, 305:1873-1881.
51.  Moulder S, Yan K, Huang F, Hess KR, Liedtke C, Lin F, Hatzis C, Hortobagyi GN, 
Symmans WF, Pusztai L: Development of candidate genomic markers to 
select breast cancer patients for dasatinib therapy. Mol Cancer Ther 2010, 
9:1120-1127.
52.  Habermann JK, Doering J, Hautaniemi S, Roblick UJ, Bündgen NK, Nicorici D, 
Kronenwett U, Rathnagiriswaran S, Mettu RK, Ma Y, Krüger S, Bruch HP, Auer G, 
Guo NL, Ried T: The gene expression signature of genomic instability in 
breast cancer is an independent predictor of clinical outcome. Int J Cancer 
2009, 124:1552-1564.
53.  Russnes HG, Vollan HK, Lingjaerde OC, Krasnitz A, Lundin P, Naume B, Sørlie T, 
Borgen E, Rye IH, Langerød A, Chin SF, Teschendorff   AE, Stephens PJ, Månér S, 
Schlichting E, Baumbusch LO, Kåresen R, Stratton MP, Wigler M, Caldas C, 
Zetterberg A, Hicks J, Børresen-Dale AL: Genomic architecture characterizes 
tumor progression paths and fate in breast cancer patients. Sci Transl Med 
2010, 2:38ra47.
54.  Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z: A signature of 
chromosomal instability inferred from gene expression profi  les predicts 
clinical outcome in multiple human cancers. Nat Genet 2006, 38:1043-1048.
55.  Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, 
van de Rijn M, Botstein D, Brown PO: Gene expression signature of 
fi  broblast serum response predicts human cancer progression: similarities 
between tumors and wounds. PLoS Biol 2004, 2:E7.
56.  Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, 
Kristensen GB, Helland A, Børresen-Dale AL, Giaccia A, Longaker MT, Hastie T, 
Yang GP, van de Vijver MJ, Brown PO: Gene expression programs in 
response to hypoxia: cell type specifi  city and prognostic signifi  cance in 
human cancers. PLoS Med 2006, 3:e47.
57.  Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, 
Shedden K, Clarke MF: The prognostic role of a gene signature from 
tumorigenic breast-cancer cells. N Engl J Med 2007, 356:217-226.
58.  Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, 
Gerald WL, Massague J: Genes that mediate breast cancer metastasis to 
lung. Nature 2005, 436:518-524.
59.  Narod SA, Foulkes WD: BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 
2004, 4:665-676.
60.  Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, Kok CY, Jia M, 
Ewing R, Menzies A, Teague JW, Stratton MR, Futreal PA: COSMIC (the 
Catalogue of Somatic Mutations in Cancer): a resource to investigate 
acquired mutations in human cancer. Nucleic Acids Res 2010, 38:D652-657.
61.  Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, 
Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH: The PIK3CA gene 
is mutated with high frequency in human breast cancers. Cancer Biol Ther 
2004, 3:772-775.
62.  Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, 
Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen 
TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and 
survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
63.  Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, 
Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, 
Kalicki J, Zhang Q, Chen L, Lin L, Wendl MC, McMichael JF, Magrini VJ, Cook L, 
McGrath SD, Vickery TL, Appelbaum E, Deschryver K, Davies S, Guintoli T, Lin 
L, et al.: Genome remodelling in a basal-like breast cancer metastasis and 
xenograft. Nature 2010, 464:999-1005.
64.  Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, 
Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore 
R, Severson T, Taylor GA, Teschendorff   AE, Tse K, Turashvili G, Varhol R, Warren 
RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S: 
Mutational evolution in a lobular breast tumour profi  led at single 
nucleotide resolution. Nature 2009, 461:809-813.
65.  Wang P, Whiteaker JR, Paulovich AG: The evolving role of mass spectrometry 
in cancer biomarker discovery. Cancer Biol Ther 2009, 8:1083-1094.
66.  Yocum AK, Chinnaiyan AM: Current aff  airs in quantitative targeted 
proteomics: multiple reaction monitoring-mass spectrometry. Brief Funct 
Genomic Proteomic 2009, 8:145-157.
67.  Kuzyk MA, Smith D, Yang J, Cross TJ, Jackson AM, Hardie DB, Anderson NL, 
Borchers CH: Multiple reaction monitoring-based, multiplexed, absolute 
quantitation of 45 proteins in human plasma. Mol Cell Proteomics 2009, 
8:1860-1877.
68.  Domanski D, Murphy LC, Borchers CH: Assay development for the 
determination of phosphorylation stoichiometry using multiple reaction 
monitoring methods with and without phosphatase treatment: 
application to breast cancer signaling pathways. Anal Chem 2010, 
82:5610-5620.
69.  Leth-Larsen R, Lund R, Hansen HV, Laenkholm AV, Tarin D, Jensen ON, Ditzel 
HJ: Metastasis-related plasma membrane proteins of human breast cancer 
cells identifi  ed by comparative quantitative mass spectrometry. Mol Cell 
Proteomics 2009, 8:1436-1449.
70.  Zach O, Lutz D: Tumor cell detection in peripheral blood and bone marrow. 
Curr Opin Oncol 2006, 18:48-56.
71.  Gerges N, Rak J, Jabado N: New technologies for the detection of 
circulating tumour cells. Br Med Bull 2010, 94:49-64.
72.  Pantel K, Alix-Panabieres C, Riethdorf S: Cancer micrometastases. Nat Rev Clin 
Oncol 2009, 6:339-351.
73.  Thurm H, Ebel S, Kentenich C, Hemsen A, Riethdorf S, Coith C, Wallwiener D, 
Braun S, Oberhoff   C, Janicke F, Pantel K: Rare expression of epithelial cell 
adhesion molecule on residual micrometastatic breast cancer cells after 
adjuvant chemotherapy. Clin Cancer Res 2003, 9:2598-2604.
74.  Deng G, Herrler M, Burgess D, Manna E, Krag D, Burke JF: Enrichment with 
anti-cytokeratin alone or combined with anti-EpCAM antibodies 
signifi  cantly increases the sensitivity for circulating tumor cell detection in 
metastatic breast cancer patients. Breast Cancer Res 2008, 10:R69.
75.  Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, 
Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, 
Griffi   th and Gray Breast Cancer Research 2011, 13:230 
http://breast-cancer-research.com/content/13/6/230
Page 10 of 11Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, 
Pantel K: A pooled analysis of bone marrow micrometastasis in breast 
cancer. N Engl J Med 2005, 353:793-802.
76.  De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, 
Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M: 
Circulating tumor cells and bone metastases as detected by FDG-PET/CT 
in patients with metastatic breast cancer. Ann Oncol 2010, 21:33-39.
77.  Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, 
Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker 
K, Kasimir-Bauer S, Wallwiener D, Pantel K: HER2 status of circulating tumor 
cells in patients with metastatic breast cancer: a prospective, multicenter 
trial. Breast Cancer Res Treat 2010, 124:403-412.
78.  Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch 
M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen 
LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW: Circulating tumor cells in 
patients with breast cancer dormancy. Clin Cancer Res 2004, 10:8152-8162.
79.  Pantel K, Brakenhoff   RH, Brandt B: Detection, clinical relevance and specifi  c 
biological properties of disseminating tumour cells. Nat Rev Cancer 2008, 
8:329-340.
80.  Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A, Lee C, 
McKernan K, De La Vega FM, Kinzler KW, Vogelstein B, Diaz LA Jr, Velculescu 
VE: Development of personalized tumor biomarkers using massively 
parallel sequencing. Sci Transl Med 2010, 2:20ra14.
81.  Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings 
LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, 
Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts 
AM, Martens JW, Silver DP, Langerød A, Russnes HE, Foekens JA, Reis-Filho JS, 
van ‘t Veer L, Richardson AL, Børresen-Dale AL, et al.: Complex landscapes of 
somatic rearrangement in human breast cancer genomes. Nature 2009, 
462:1005-1010.
82.  Jones SJ, Laskin J, Li YY, Griffi   th OL, An J, Bilenky M, Butterfi  eld YS, Cezard T, 
Chuah E, Corbett R, Fejes AP, Griffi   th M, Yee J, Martin M, Mayo M, Melnyk N, 
Morin RD, Pugh TJ, Severson T, Shah SP, Sutcliff  e M, Tam A, Terry J, Thiessen N, 
Thomson T, Varhol R, Zeng T, Zhao Y, Moore RA, Huntsman DG, et al.: 
Evolution of an adenocarcinoma in response to selection by targeted 
kinase inhibitors. Genome Biol 2010, 11:R82.
83.  Birdwell RL, Mountford CE, Iglehart JD: Molecular imaging of the breast. AJR 
Am J Roentgenol 2009, 193:367-376.
84.  Stanwell P, Gluch L, Clark D, Tomanek B, Baker L, Giuff  re B, Lean C, Malycha P, 
Mountford C: Specifi  city of choline metabolites for in vivo diagnosis of 
breast cancer using 1H MRS at 1.5 T. Eur Radiol 2005, 15:1037-1043.
85.  Pan L, Han Y, Sun X, Liu J, Gang H: FDG-PET and other imaging modalities 
for the evaluation of breast cancer recurrence and metastases: a meta-
analysis. J Cancer Res Clin Oncol 2010, 136:1007-1022.
86.  Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A: 
Comparison of triple-negative and estrogen receptor-positive/
progesterone receptor-positive/HER2-negative breast carcinoma using 
quantitative fl  uorine-18 fl  uorodeoxyglucose/positron emission 
tomography imaging parameters: a potentially useful method for disease 
characterization. Cancer 2008, 112:995-1000.
87.  Dietzel M, Baltzer PA, Vag T, Groschel T, Gajda M, Camara O, Kaiser WA: 
Application of breast MRI for prediction of lymph node metastases - 
systematic approach using 17 individual descriptors and a dedicated 
decision tree. Acta Radiol 2010, 51:885-894.
88.  Ma J, Costelloe CM, Madewell JE, Hortobagyi GN, Green MC, Cao G, Sun F, 
Kundra V: Fast dixon-based multisequence and multiplanar MRI for whole-
body detection of cancer metastases. J Magn Reson Imaging 2009, 
29:1154-1162.
89.  Cai W, Chen X: Nanoplatforms for targeted molecular imaging in living 
subjects. Small 2007, 3:1840-1854.
90.  Kramer-Marek G, Kiesewetter DO, Capala J: Changes in HER2 expression in 
breast cancer xenografts after therapy can be quantifi  ed using PET and 
(18)F-labeled affi   body molecules. J Nucl Med 2009, 50:1131-1139.
91. Khatcheressian  JL,  Wolff   AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, Halberg 
F, Somerfi  eld MR, Davidson NE: American Society of Clinical Oncology 2006 
update of the breast cancer follow-up and management guidelines in the 
adjuvant setting. J Clin Oncol 2006, 24:5091-5097.
92.  Creative Commons Attribution 3.0 Unported [http://creativecommons.org/
licenses/by/3.0/deed.en]
93.  Creative Commons Attribution-Share Alike 3.0 Unported [http://
creativecommons.org/licenses/by-sa/3.0/deed.en]
doi:10.1186/bcr2923
Cite this article as: Griffi   th OL, Gray JW: ‘Omic approaches to preventing or 
managing metastatic breast cancer. Breast Cancer Research 2011, 13:230.
Griffi   th and Gray Breast Cancer Research 2011, 13:230 
http://breast-cancer-research.com/content/13/6/230
Page 11 of 11